Pharma Companies Will Not Present At Second IoM Drug Review Meeting
This article was originally published in The Pink Sheet Daily
No pharmaceutical industry representatives are scheduled to speak during the open public forum of the July 19-20 IoM drug safety review meeting
You may also be interested in...
The Institute of Medicine’s second meeting on the U.S. drug safety system will also include presentations from FDA, CMS and AHRQ on their role in drug safety. Other scheduled speakers include a series of consumer representatives.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.